INmune Bio Management
Management criteria checks 2/4
INmune Bio's CEO is RJ Tesi, appointed in Sep 2015, has a tenure of 9.33 years. total yearly compensation is $1.69M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 7.01% of the company’s shares, worth $8.66M. The average tenure of the management team and the board of directors is 9.3 years and 8.1 years respectively.
Key information
RJ Tesi
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 29.5% |
| CEO tenure | 9.3yrs |
| CEO ownership | 7.0% |
| Management average tenure | 9.3yrs |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Nov 03
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
Sep 30It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year
Jul 12Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$2m | US$501k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$1m | US$455k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$33m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$3m | US$455k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$300k | US$300k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$1m | US$248k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$3m | US$120k | -US$12m |
Compensation vs Market: RJ's total compensation ($USD1.69M) is above average for companies of similar size in the US market ($USD641.95K).
Compensation vs Earnings: RJ's compensation has increased whilst the company is unprofitable.
CEO
RJ Tesi (68 yo)
9.3yrs
Tenure
US$1,694,818
Compensation
Dr. Raymond Joseph Tesi, MD, also known as RJ, serves as Director at Bexion Pharmaceuticals, Inc. Dr. Tesi is the Co-Founder of INmuneBio Inc. and has been its Chief Medical Officer and Chairman and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | US$1.69m | 7.01% $ 8.7m | |
| CFO, Treasurer & Secretary | 9.3yrs | US$1.59m | 5.8% $ 7.2m | |
| Chief Scientific Officer & Chief Manufacturing Officer | 9.3yrs | US$150.24k | 6.81% $ 8.4m | |
| General Counsel | 6yrs | no data | no data |
9.3yrs
Average Tenure
61yo
Average Age
Experienced Management: INMB's management team is seasoned and experienced (9.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | US$1.69m | 7.01% $ 8.7m | |
| Independent Director | 5.2yrs | US$301.66k | no data | |
| Independent Director | 6.8yrs | US$301.66k | 0.32% $ 398.8k | |
| Independent Director | 8.3yrs | US$301.66k | 0.080% $ 99.1k | |
| Independent Director | 8.1yrs | US$301.26k | 0.37% $ 457.8k |
8.1yrs
Average Tenure
66yo
Average Age
Experienced Board: INMB's board of directors are considered experienced (8.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 16:16 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
INmune Bio, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Joel Beatty | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |